Malignant Peritoneal Neoplasm
Associated Genetic Biomarkers
NCI Definition: A primary or metastatic malignant neoplasm involving the peritoneum. Representative examples include carcinoma and malignant mesothelioma. 
Of the biomarker-directed therapies for malignant peritoneal neoplasm, 0 are FDA-approved in at least one setting and 0 have NCCN guidelines in at least one setting .
Disease is predicted to be sensitive: -
There are 2 clinical trials for malignant peritoneal neoplasm, of which 2 are open and 0 are completed or closed. Of the trials that contain malignant peritoneal neoplasm as an inclusion criterion, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open).
Dkn-01, dpx-survivac, and cyclophosphamide are the most common interventions in malignant peritoneal neoplasm clinical trials.
Significant Genes in Malignant Peritoneal Neoplasm
Olaparib has evidence of efficacy in patients with BRCA1 mutation in malignant peritoneal neoplasm .
Olaparib has evidence of efficacy in patients with BRCA2 mutation in malignant peritoneal neoplasm .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.